Get the Weekly Intelligence Brief — top committee picks every Sunday.
STE · NYSE · STOCK

Steris (STE) Stock Analysis

Healthcare Updated August 17, 2026
$229.85
52W $195.14 – $269.44
59/100
$22.73B
28.4
0.91
AI Committee Verdict
Watch
59/100
Conviction: High · 83% agreement · 6 analysts
+8.4%
-0.3%
31.07:1
High

Is STE Bullish or Bearish?

Mixed. Innellis AI committee rates Steris (STE) Watch with a composite score of 59/100 , based on 6 analysts with 83% agreement. Last updated August 17, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +1.24 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -18.76 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • EPS growing 27.9% YoY — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Low leverage (debt-to-equity 0.27) -- balance sheet can absorb a shock — Risk
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • P/E of 29.2 is moderate-to-rich — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • Bollinger bandwidth of 17.8% signals elevated volatility — Risk
  • Negative filing: Costs associated with exit or disposal (restructuring) (12d ago) — News
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 17, 2026
Overall Committee Score
59/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 55%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 29.2 is moderate-to-rich
Growth Analyst neutral
53 / 100 · High confidence
Moderate growth -- present but not remarkable
+ EPS growing 27.9% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.27) -- balance sheet can absorb a shock
− Bollinger bandwidth of 17.8% signals elevated volatility
Macro Analyst bullish
80 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
48 / 100 · Moderate confidence
News flow is mixed or quiet -- no strong signal either way right now
− Negative filing: Costs associated with exit or disposal (restructuring) (12d ago)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 58.8 to 58.8.

Analyst-level changes:
  • News Analyst: +1 bearish signal(s).
  • Portfolio Manager: +1 bearish signal(s).

Comparing 2026-08-16 to 2026-08-17 (1 day apart).

Technical Analysis

RSI (14)
53.5
Neutral
MACD Histogram
0.135
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$232.56
Resistance
$252.76
Bollinger %B
0.63
Inside Bands
Price vs Moving Averages
EMA 9
$234.25 Below
EMA 21
$229.02 Above
EMA 50
$222.57 Above
EMA 200
$227.49 Above

Fundamental Analysis

Valuation
71
Growth
48
Profitability
64
Financial Health
96
Cash Flow
70
Valuation
P/E Ratio 28.4×
P/B Ratio 3.16×
PEG Ratio 1.14
Dividend Yield 1.08%
52W High $269.44
52W Low $195.14
Quality & Growth
ROE 1092.9%
ROA 731.2%
Gross Margin 4443.4%
Operating Margin 1890.8%
Revenue Growth YoY
Debt / Equity 0.28
AI Fundamental Assessment
P/E ratio of 28.4 (moderate relative to a 15-40x range); Price-to-book of 3.2x; PEG ratio of 1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.9%; Return on assets of 7.3%; Net margin of 13.3%; Gross margin of 44.4%; Current ratio of 1.91 (healthy short-term liquidity); Debt-to-equity of 0.28; Free cash flow per share is positive (9.48); Most recent quarter beat estimates by 2.5%; EPS growth decelerating (+11.9% -> -8.5% QoQ); Average YoY EPS growth of 10.7%; Analyst estimates flat over recent quarters
Get the Full STE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore STE Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime